Business Wire

ADRESTIA

18.5.2022 12:32:09 CEST | Business Wire | Press release

Share
Adrestia Appoints Human Genetics Leader, Professor John Perry, to Build Human Genetics Computational Platform

Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases, today announced the appointment of Professor John R.B. Perry as its Vice President, Human Genetics. Dr Perry is a world-renowned expert in human population genetics at the University of Cambridge with a track record of identifying genetic drivers of complex, multigenic diseases and health-related traits. His expertise will complement Adrestia’s technology platform, which is already progressing a series of first-in-class therapies to treat both rare and common diseases with a genetic component.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005013/en/

“We are on the cusp of a revolution in drug discovery” said Dr Perry. “Within the 8 billion living humans, each single base substitution in the genome that is compatible with life is likely to be present somewhere. Studying this genetic diversity in population studies gives us a hypothesis-free, genome wide screen for identifying and validating genes causing or influencing human disease. Due to advances in genome sequencing technologies and the advent of large-scale population studies, we can now phenotype human genetic knockouts at scale, leading to rapid validation of new drug discovery targets.” said Dr Perry. “I’m excited to apply these advanced techniques for maximum clinical impact. Combining population genetics with Adrestia’s synthetic rescue platform provides unprecedented opportunities to efficiently unlock new ways of treating some of the world’s most intractable diseases”.

Throughout his career and in recent years at the University of Cambridge, Professor Perry has been involved in discovering many of the first genetic drivers of diverse complex diseases including obesity, Type 2 diabetes, reproductive disorders and aspects of behavior. His work to better understand the genetic architecture of disease will enable more efficient drug target selection and the design of more predictive models of disease, both translating into higher drug development success rates. His career has been deeply embedded in the UK’s world-leading projects in population genomic analysis, including the UK Biobank, a ground-breaking resource containing in-depth genetic and health information from half a million participants. These projects have created deep expertise and an infrastructure that can be further leveraged for effective drug development at Adrestia.

Despite advances in genetic technologies, many genes known to directly cause disease remain undruggable. Synthetic rescue offers a fresh approach: rather than targeting the causative mutation, a synthetic rescue drug modulates the product of another, functionally connected gene, correcting the effects of the disease mutation and ‘rescuing’ cells from disease. The concept is underpinned by a deep understanding of genetic networks, and its therapeutic potential is illustrated in families where a member born with a disease-causing mutation is protected from disease due to a second ‘rescue’ mutation. Synthetic rescue presents new opportunities for drug development across all diseases that have a genetic component, including prevalent conditions.

“Traditional drug development is risky and expensive” said Robert Johnson, Chief Executive Officer of Adrestia. “We believe that our synthetic rescue platform, supplemented by John’s expertise in human genetics, offers a new paradigm, where the probability of success is markedly higher, the cost of development is dramatically lower and the time to clinical proof of concept is substantially shorter. We warmly welcome John to our team, which is united in a singular mission: to deliver revolutionary new medicines to patients suffering from devastating diseases”.

Dr Perry is Professor of Molecular Endocrinology at the University of Cambridge and Medical Research Council (MRC) Programme Leader and Investigator at the University’s Institute of Metabolic Science. He also serves as an Associate Group Leader at The Gurdon Institute at the University of Cambridge, as well as being a Fellow and Director of Studies at King’s College Cambridge. He will continue in these roles while serving at Adrestia.

Prior to joining the MRC Epidemiology Unit, Dr Perry was a Sir Henry Wellcome Fellow, holding visiting positions at the University of Exeter Medical School; the Wellcome Trust Centre for Human Genetics at the University of Oxford; the Department of Twin Research at Kings College London and the Center for Statistical Genetics at the University of Michigan. He has co-authored over 150 publications in peer reviewed journals, many in leading journals such as Nature, Science, Nature Genetics and Nature Medicine. Dr Perry completed his Ph.D. in Human Genetics at the University of Exeter, UK and before then had a background in computer science.

About Adrestia’s synthetic rescue platform

Adrestia has developed a leading synthetic rescue drug development platform, which has already identified completely new approaches to treating intractable genetic diseases. The platform includes multiple components, each designed to yield new insights into how every gene in the human genome modifies a particular disease’s cellular phenotype. These insights are married with human genetic datasets to provide robust validation of new druggable targets and build an ever-growing synthetic rescue ‘Atlas’ of the human genome. As the Atlas expands, the opportunities to use synthetic rescue drugs to treat both rare and common diseases continue to grow.

This scalable platform builds on decades of research by Professor Steve Jackson’s laboratory at the University of Cambridge into synthetic rescue and the related concept of synthetic lethality for the treatment of cancer. The Jackson Laboratory’s work has yielded a wealth of concepts, techniques, and know-how, now translated into Adrestia’s platform.

About Adrestia

Adrestia is a leader in synthetic rescue therapies for genetic diseases. As many directly causative mutations are not druggable, synthetic rescue embraces the much broader target set represented by functionally connected genes, to correct the effects of the causative mutations and ‘rescue’ health. Adrestia is creating a synthetic rescue ‘Atlas’ of the human genome and advancing a portfolio of first-in-class therapies, initially for neurologic, neuromuscular and cardiomyopathic diseases. Adrestia’s platform and in-house programs are complemented by a target discovery alliance with GSK and a Huntington’s disease collaboration with noted researchers including Dr Sarah Tabrizi at University College London.

Adrestia was co-founded by Professor Steve Jackson and the deep technology investment fund Ahren Innovation Capital, which co-led Adrestia’s Series A financing along with GSK. Jackson co-originated the first synthetic lethality drug, olaparib, which was the first drug approved to treat cancers caused by inherited mutations. For further information, please visit: http://www.adrestia.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release

Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro

SES to Develop European Direct-to-Device Technologies under ESA Partnership Project17.11.2026 15:30:00 CET | Press release

The new SELYCE programme supports transition towards hybrid networks to strengthen Europe’s critical communications infrastructures SES today announced it will lead the industrial activities of SELYCE, a new European initiative focused on developing the technologies needed to enable future Direct-to-Device (D2D) satellite services. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117544892/en/ SES to Develop European Direct-to-Device Technologies under ESA Partnership Project Conducted under a Partnership Project with the European Space Agency (ESA) and supported by the Luxembourg Space Agency (LSA), Belgian Science Policy Office (BELSPO) and UK Space Agency (UKSA), SELYCE brings together European industry and research organisations to advance standards-based 5G Non-Terrestrial Network (NTN) capabilities that will allow everyday smartphones and IoT devices to connect seamlessly via satellite beyond the reach of terrestrial

From returns to restaurant bookings: Klarna’s AI assistant finds the best product & price, buys it for you, and you don’t pay until it arrives17.11.2026 15:26:00 CET | Press release

The Klarna AI-assistant takes the admin off your hands, on WhatsApp and iMessage. Waitlist opens today Klarna, the everyday finance network, today announced the Klarna AI-assistant, a personal assistant that handles shopping, returns, bookings, and everyday admin, so you don’t have to. Currently live with a small group of early users, the AI-assistant acts like a personal concierge, handling tasks on each customer’s behalf while keeping them firmly in control. Waitlist opens this week. The Klarna AI-assistant finds options and helps people decide, books anything from a table for two, to a babysitter, and keeps track of what they’re waiting for. It drafts email replies for approval, files receipts, and flags upcoming birthdays with gift ideas. This new AI-assistant builds on Klarna’s shopping assistant, a popular feature in its app. Klarna customers have spent more than $34 billion through the app’s built-in browser since 2020, a feature that lets you shop any website, including stores

Impartner Launches MCP Server to Connect AI Assistants with Live PRM Data17.11.2026 15:19:00 CET | Press release

Impartner MCP gives partner program teams conversational access to live partner pipeline, deal registration and account data through supported AI assistants, while maintaining existing user permissions and data access controls. Impartner, the world's leading partner revenue orchestration platform, today announced the launch of Impartner MCP, enabling organizations to connect AI assistants directly to live partner relationship management (PRM) data. Powered by the Model Context Protocol (MCP), an open standard for connecting AI assistants with external systems and data sources, the integration makes Impartner PRM information accessible within supported AI environments without requiring users to navigate multiple reports and dashboards. With Impartner MCP, teams can ask natural-language questions about partner pipelines, deal registrations, account activity and program performance, receiving answers grounded in real-time operational data and governed by their existing access permissions.

Incode Launches Incode Know Your Agent to Anchor AI Agent Trust in Verified Human Identity17.11.2026 15:14:00 CET | Press release

Businesses can now verify the human behind every AI agent acting on behalf of their customers and get access, control, and visibility over everything it does Incode, the identity platform trusted by more than 800 organizations, including nine of the top 10 US banks, eight of the top nine US telcos, and four of the top five global marketplaces, today launched Incode Know Your Agent, which ties every AI agent to a verified person and to the mandate that person set. With Incode Know Your Agent, businesses can get access, control, and visibility over every agent that acts on behalf of their customers. AI agents already act on behalf of people in banking, commerce, and everyday services. A fraudster’s agent can arrive with the same valid credentials as a customer’s, making it impossible for a business to tell them apart. AI agents are creating a new kind of economy, and fraud is growing inside it. Nearly seven in 10 Americans (69%) say they would let a bank’s AI assistant complete at least

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye